What do systematic reviews say?

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Very low

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.5 [0.06, 34.66]
  1 study · 29 participants
  Very low

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.39 [0.71, 2.7]
  1 study · 29 participants
  Low

Lanadelumab vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 83 participants
  Low

Lanadelumab vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lanadelumab vs placebo or active control

Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.88 [0.08, 10.39]
  2 studies · 162 participants
  Low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Low

Lanadelumab vs placebo or active control

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.07 [0.77, 1.47]
  2 studies · 158 participants
  Low

Berotralstat vs placebo or active control

Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.63 [0.39, 1]
  1 study · 37 participants
  Low

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 130 participants
  Low

Antibiotics vs placebo

Antibiotics showed no clear difference in failure to induce clinical remission at end of study compared with placebo (high certainty).

• Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes only
  RR 0.88 [0.74, 1.06]
  7 studies · 608 participants
  High

Antibiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

It is very uncertain whether antibiotics changes failure to induce clinical response at end of study compared with 5‐ASA (very low certainty).

• Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes only
  RR 2.2 [1.17, 4.14]
  1 study · 46 participants
  Very low

Antibiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

• Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  GRADE not reported

Antibiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

• Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  GRADE not reported